medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2022, Number 2

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2022; 20 (2)

Low-power capillary laser in contemporary therapy of androgenetic alopecia: A contemporary review of the literature

Méndez BSI

Language: Spanish
References: 43
Page: 216-224
PDF size: 328.97 Kb.


ABSTRACT

Androgenetic alopecia (AGA) is a multifactorial entity that affects both men and women and has a great social and psychological impact. Contemporary AGA treatment uses a wide range of tools. Current research is constantly looking for new treatments that can modify the capillary morphogenesis pathways as possible therapeutic agents.
In this work, we make an updated review of the treatment with low-level laser therapy within the therapeutic arsenal for AGA. An unstructured PubMed engine search was performed within the Medline database using the mesh terms: Androgenetic alopecia, Hair loss, Hair regrowth, Low-level light therapy and Lowlevel laser therapy. A narrative review was written, oriented to a clinical perspective, describing the current role of the LLL in the treatment of AGA.
The current level of evidence for this therapy is supported by over a dozen of clinical trials, demonstrating its efficacy in the treatment of aga in both men and women, either alone or as an adjunct therapy to topical agents. While there is no established value for the best wavelength for LLL, most studies use therapeutic wavelengths ranging from 500-1 100 nm with a power density of 3 to 90 mw/cm2 and fluency of 1 to 4 J/cm2.
While the efficacy of LLL therapy is not in question, exact data to support this configuration is still lacking. Further research should be aimed at standardizing the appropriate LLL output power and wavelength for the specific treatment of AGA. Furthermore, more studies are needed to reinforce the long-term safety of this approach.


REFERENCES

  1. Yousuf Azeemi ST y Raza SM, A critical analysis of chromotherapyand its scientific evolution. Evidence-based, Complement Altern Med 2005; 2(4):481-8.

  2. Sorbellini E, Rucco M y Rinaldi F, Photodynamic and photobiologicaleffects of light-emitting diode (led) therapy in dermatological disease:an update, Lasers Med Sci 2018; 33(7):1431-9.

  3. Avram MR y Rogers NE, The use of low-level light for hair growth:Part 1, J Cosmet Laser Ther 2009; 11(2):110-7.

  4. Townes CH, Theodore H., Maiman (1927-2007), Nature 2007;447(7145):654.

  5. Gibson KF y Kernohant WG, Lasers in medicine: a review, J Med EngTechnol 1993; 17(2):51.

  6. Posten W, Wrone DA, Dover JS, Arndt KA, Silapunt S y Alam M,Low-level laser therapy for wound healing: mechanism and efficacy,Dermatologic Surg. 2006; 31(3):334-40.

  7. Farivar S, Malekshahabi T y Shiari R, Biological effects of low level lasertherapy, J Lasers Med Sci 2014; 5(2):58-62.

  8. Blanpain C y Fuchs E, Epidermal stem cells of the skin, Annu Rev Cell DevBiol 2006; 22(1):339-73.

  9. Premanand A y Reena Rajkumari B, Androgen modulation of wnt/β-catenin signaling in androgenetic alopecia, Arch Dermatol Res 2018;310(5):391-9.

  10. Leirõs GJ, Attorresi AI y Balañá ME, Hair follicle stem cell differentiationis inhibited through cross-talk between wnt/β-catenin andandrogen signalling in dermal papilla cells from patients with androgeneticalopecia, Br J Dermatol 2012; 166(5):1035-42.

  11. Sasaki GH, Review of human hair follicle biology: dynamics of nichesand stem cell regulation for possible therapeutic hair stimulation forplastic surgeons, Aesthetic Plast Surg 2019; 43(1):253-66.

  12. Stevens J y Khetarpal S, Platelet-rich plasma for androgenetic alopecia:a review of the literature and proposed treatment protocol, IntJ Women’s Dermatology 2019; 5(1): 46-51.

  13. Carolina A, De Barcelos F, Catarina S y Monte CA, Safety and efficacyof a topical treatment (sm04554) for androgenetic alopecia(aga): results from a phase 1 trial, J Am Acad Dermatol 2016; 74(5):ab138.

  14. Najem I y Chen H, Use of low-level laser therapy in treatment of theandrogenic alopecia, the first systematic review, J Cosmet Laser Ther2018; 20(4):252-7.

  15. Darwin E, Heyes A, Hirt PA, Wikramanayake TC y Jiménez JJ, Lowlevellaser therapy for the treatment of androgenic alopecia: a review,Lasers Med Sci 2018; 33(2):425-34.

  16. Hamblin MR, Photobiomodulation for the management of alopecia:mechanisms of action, patient selection and perspectives, Clin CosmetInvestig Dermatol 2019; 12:669-78.

  17. Ellis JA, Sinclair R y Harrap SB, Androgenetic alopecia: pathogenesisand potential for therapy, Expert Rev Mol Med 2002; 19:4(22):1-11.

  18. Zhu K, Xu C, Liu M y Zhang J, Hairless controls hair fate decisionvia wnt/β-catenin signaling, Biochem Biophys Res Commun 2017; 491(3):567-70.

  19. Kim JT, Weiss HL, Liu C, Wang Q y Evers BM, Tu1153: regulationof ketogenesis by wnt/β-catenin/Pparγ signaling in human colorectalcancer cells, Gastroenterology 2019; 156(6):s-965.

  20. Hunt N y McHale S, The psychological impact of alopecia, Psychologist2007; 20(6):362-4.

  21. Cartwright T, Endean N y Porter A, Illness perceptions, coping andquality of life in patients with alopecia, Br J Dermatol 2009; 160(5):1034-9.

  22. Springer K, Brown M y Stulberg DL, Common hair loss disorders, AmFam Physician 2003; 68(1):93-102.

  23. Ceruti JM, Leirós GJ y Balañá ME, Androgens and androgen receptoraction in skin and hair follicles, Mol Cell Endocrinol 2018; 465:122-33.

  24. Lingala SM, Ghany MG, Jo SJ, Shin HJ, Park YW, Paik SH et al., Baicalinincreases hair follicle development by increasing canonical wnt/β-catenin signaling and activating dermal papillar cells in mice, Gastroenterology2016; 41(4):2079-85.

  25. Michel L, Reygagne P, Benech P, Jean-Louis F, Scalvino S, Ly K, So S etal., Study of gene expression alteration in male androgenetic alopecia:evidence of predominant molecular signalling pathways, Br J Dermatol2017; 177(5):1322-36.

  26. Leirós GJ, Ceruti JM, Castellanos ML, Kusinsky AG y Balañá ME,Androgens modify wnt agonists/antagonists expression balance indermal papilla cells preventing hair follicle stem cell differentiation inandrogenetic alopecia, Mol Cell Endocrinol 2017; 439:26-34.

  27. Kanti V, Messenger A, Dobos G, Reygagne P, Finner A, Blumeyer A etal., Evidence-based (S3) guideline for the treatment of androgeneticalopecia in women and in men: short version, J Eur Acad DermatologyVenereol 2018; 32(1):11-22.

  28. Lee WS, Lee HJ, Choi GS, Cheong WK, Chow SK, Gabriel MT et al.,Guidelines for management of androgenetic alopecia based on baspclassification-the Asian consensus committee guideline, J Eur Acad DermatologyVenereol 2013; 27(8):1026-34.

  29. Suchonwanit P, Thammarucha S y Leerunyakul K, Minoxidil and itsuse in hair disorders: a review, Drug Des Devel Ther 2019; 13:2777-86.

  30. Rogers NE, Avram MR, Medical treatments for male and female patternhair loss, J Am Acad Dermatol 2008; 59(4):547-66.

  31. Mester E, Szende B y Gärtner P, The effect of laser beams on thegrowth of hair in mice, Radiobiol Radiother (Berlín) 1968; 9(5):621-6. Disponibleen: http://www.ncbi.nlm.nih.gov/pubmed/5732466.

  32. Satino JL y Markou M, Hair regrowth and increased hair tensilestrength using the HairMax LaserComb for low-level laser therapy, IntJ Cosmet Surg Aesthetic Dermatology, 2003; 5(2):113-7.

  33. Leavitt M, Charles G, Heyman E y Michaels D, HairMax LaserComb®laser phototherapy device in the treatment of male androgenetic alopecia:a randomized, double-blind, sham device-controlled, multicentretrial, Clin Drug Investig 2009; 29(5):283-92.

  34. Lanzafame RJ, Blanche RR, Bodian AB, Chiacchierini RP, Fernández-Obregón A y Kazmirek ER, The growth of human scalp hair mediatedby visible red light laser and led sources in males, Lasers Surg Med 2013;45(8):487-95.

  35. Lanzafame RJ, Blanche RR, Chiacchierini RP, Kazmirek ER y Sklar JA,The growth of human scalp hair in females using visible red light laserand led sources, Lasers Surg Med 2014; 46(8):601-7.

  36. Krebs EE, Gravely A, Nugent S, Jensen AC, DeRonne B, Goldsmith ESet al., Effect of opioid vs nonopioid medications on pain-related functionin patients with chronic back pain or hip or knee osteoarthritispain, jama 2018; 319(9):872.

  37. Baxter GD, Liu L, Petrich S, Gisselman AS, Chapple C, Anders JJ etal., Low level laser therapy (photobiomodulation therapy) for breastcancer-related lymphedema: a systematic review, bmc Cancer 2017;17(1):833.

  38. Liu KH, Liu D, Chen YT y Chin SY, Comparative effectiveness of lowlevellaser therapy for adult androgenic alopecia: a system review andmeta-analysis of randomized controlled trials, Lasers Med Sci 2019;34(6):1063-9.

  39. Kim H, Choi JW, Kim JY, Shin JW, Lee S y Huh CH, Low-level lighttherapy for androgenetic alopecia: a 24-week, randomized, doubleblind,sham device–controlled multicenter trial, Dermatologic Surg 2013;39(8):1177-83.

  40. Jiménez JJ, Wikramanayake TC, Bergfeld W, Hordinsky M, HickmanJG, Hamblin MR et al., Efficacy and safety of a low-level laser devicein the treatment of male and female pattern hair loss: a multicenter,randomized, sham device-controlled, double-blind study, Am J ClinDermatol 2014; 15(2):115-27.

  41. Consejo de Salubridad General, Diagnóstico y tratamiento de alopeciaandrogénica. Guía práctica clínica semar 2015. Disponible en: http://www.cenetec.salud.gob.mx/descargas/gpc/CatalogoMaestro/566_GPC_Alopeciaandrogenetica/566GRR.pdf.

  42. Guzmán-Sánchez DA, Alopecia androgenética, Dermatologia Rev Mex2015; 59(5):387-94.

  43. Munck A, Gavazzoni MF y Trüeb RM, Use of low-level laser therapyas monotherapy or concomitant therapy for male and female androgeneticalopecia, Int J Trichology 2014; 6(2):45-9.




2020     |     www.medigraphic.com